CN114848695A - Composition of rare ginsenoside and American ginseng polysaccharide and application thereof - Google Patents

Composition of rare ginsenoside and American ginseng polysaccharide and application thereof Download PDF

Info

Publication number
CN114848695A
CN114848695A CN202210298951.6A CN202210298951A CN114848695A CN 114848695 A CN114848695 A CN 114848695A CN 202210298951 A CN202210298951 A CN 202210298951A CN 114848695 A CN114848695 A CN 114848695A
Authority
CN
China
Prior art keywords
rare ginsenoside
rare
composition
american ginseng
ginsenoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210298951.6A
Other languages
Chinese (zh)
Inventor
薛鹏
张若愚
宋林梦
荆金金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weifang Medical University
Original Assignee
Weifang Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weifang Medical University filed Critical Weifang Medical University
Priority to CN202210298951.6A priority Critical patent/CN114848695A/en
Publication of CN114848695A publication Critical patent/CN114848695A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a composition of rare ginsenoside and American ginseng polysaccharide and application thereof, which solve the technical problem of limitation of rare ginsenoside in-vivo antibiosis, wherein the composition comprises the rare ginsenoside and American ginseng polysaccharide, and the weight part ratio of the rare ginsenoside to the American ginseng polysaccharide is 1:3-3:1, the rare ginsenoside comprises rare ginsenoside Rb2, rare ginsenoside Rd, rare ginsenoside Rg6, rare ginsenoside F4, rare ginsenoside Rh4, rare ginsenoside Rg3, rare ginsenoside Rk1, rare ginsenoside Rg5 and rare ginsenoside Rh 2. The invention also provides the application of the composition of the rare ginsenoside and the American ginseng polysaccharide in the preparation of drugs and/or health products for resisting drug-resistant bacterial infection, and the composition can be widely applied to the technical field of pharmaceutical preparations.

Description

Composition of rare ginsenoside and American ginseng polysaccharide and application thereof
Technical Field
The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a composition of rare ginsenoside and American ginseng polysaccharide and application thereof.
Background
Drug-resistant bacterial pathogenic bacteria infection is a public health problem which is not negligible in the world at present, and generally causes serious injury to infants, preschool children, pregnant and lying-in women and old people. According to the statistics of the world health organization in the last decade, among various diseases caused by bacterial pathogen infection in the world, the death cases caused by only bacterial encephalopathy can reach 25 ten thousand. In China, the damage caused by the infection of drug-resistant bacteria and pathogenic bacteria still exists. The currently used pharmaceutical antibiotics for drug-resistant bacterial pathogenic infections, which are used in the first line of the clinic, have a number of disadvantages: potential allergic reactions; the generation of pathogenic bacteria drug resistance; liver and kidney toxicity exists in infants; the long-term use can cause nausea, vomiting and other gastrointestinal discomfort reactions. Therefore, there is an urgent need for new drugs to replace traditional antibiotics.
The rare ginsenoside has the functions of regulating intestinal flora, relieving hypertension, improving cardiovascular function, regulating nerve function, relieving chronic fatigue, etc. Because the price of the rare ginsenoside is expensive, although the rare ginsenoside is used for researching in-vitro bacteriostasis experiments, the research of the rare saponin on the infection of microorganisms in vivo is not carried out.
In addition, the traditional Chinese medicine has the principle of 'deficiency and invigoration', the rare ginsenoside has strong irritation, and if the organism is infected with bacteria and then the organism is accelerated to die, so that the use of the rare ginsenoside is greatly limited.
Disclosure of Invention
The invention aims to solve the defects of the background technology and provides a composition of rare ginsenoside and American ginseng polysaccharide and application thereof.
Therefore, the invention provides a composition of rare ginsenoside and American ginseng polysaccharide, which comprises the rare ginsenoside and American ginseng polysaccharide.
Preferably, the rare ginsenoside and the American ginseng polysaccharide are combined in a certain range, so that the remarkable synergistic effect can be shown in the aspect of antibacterial activity. If the proportion of the rare ginsenoside and the American ginseng polysaccharide in the composition is not in the range of the proportion limited by the invention, no synergistic effect or extremely small effect is achieved. In the composition, the weight part ratio of the rare ginsenoside to the American ginseng polysaccharide is 1:3-3:1 from the viewpoint of remarkable synergistic effect.
Preferably, the rare ginsenosides comprise rare ginsenosides Rb2, rare ginsenosides Rd, rare ginsenosides Rg6, rare ginsenosides F4, rare ginsenosides Rh4, rare ginsenosides Rg3, rare ginsenosides Rk1, rare ginsenosides Rg5 and rare ginsenosides Rh 2.
Preferably, the weight parts of the rare ginsenoside are as follows: comprises 2 parts of rare ginsenoside Rb2, 1 part of rare ginsenoside Rd, 10 parts of rare ginsenoside Rg6, 2 parts of rare ginsenoside F4, 8 parts of rare ginsenoside Rh4, 7 parts of rare ginsenoside Rg3, 20 parts of rare ginsenoside Rk1, 25 parts of rare ginsenoside Rg5 and 1 part of rare ginsenoside Rh 2.
The invention also provides application of the composition of the rare ginsenoside and the American ginseng polysaccharide in preparing a drug for resisting drug-resistant bacterial infection.
The invention also provides the application of the composition of the rare ginsenoside and the American ginseng polysaccharide in the preparation of the health care product for preventing drug-resistant bacterial infection.
Preferably, the rare ginsenoside is applied to a preparation for inhibiting the growth of drug-resistant bacteria.
Preferably, the American ginseng polysaccharide is applied to an auxiliary agent for reducing the irritation of the rare ginsenoside and synergistically improving the immunity.
Furthermore, the composition of the rare ginsenoside and the American ginseng polysaccharide can be used as oral medicine or food additive for human to treat or improve drug-resistant bacterial pathogenic bacteria infection such as Listeria monocytogenes. Making into oral liquid, granule, tablet, capsule, spray, plastics or other sustained release dosage forms containing radix Panacis Quinquefolii rare saponin and radix Panacis Quinquefolii polysaccharide by conventional method.
The invention has the beneficial effects that:
(1) the invention provides a composition of rare ginsenoside and American ginseng polysaccharide, which has the advantages that the rare ginsenoside and the American ginseng polysaccharide are combined under the synergistic action of the rare ginsenoside and the American ginseng polysaccharide, so that the rare ginsenoside is used for killing and inhibiting bacteria in a human body, the irritation of the rare ginsenoside is reduced and the immunity is synergistically improved due to the existence of the American ginseng polysaccharide, the death rate of drug-resistant bacterial infection of the human body is reduced, and the use limit of the rare ginsenoside and the American ginseng polysaccharide which are used independently is relieved.
(2) The invention provides a composition of rare ginsenoside and American ginseng polysaccharide, which can play a correct drug effect only when the proportion is proper, and the drug effect can be reduced and even can be adversely acted when the proportion is improper, thereby causing damage to organisms. The proportion stability of each component in the medicine composition is important. The safety problem caused by how to determine stable component proportion parameters is more and more important. On the basis, the effect difference of the rare ginsenoside and the American ginseng polysaccharide with different proportions is further researched to obtain the composition of the rare ginsenoside and the American ginseng polysaccharide, and the composition of the rare ginsenoside and the American ginseng polysaccharide is applied to preparing the drug for resisting drug-resistant bacterial infection. In addition, based on the principle, the composition of the rare ginsenoside and the American ginseng polysaccharide can also be used for preparing health-care products for preventing drug-resistant bacterial infection.
Drawings
In order to more clearly illustrate the technical solutions in the embodiments of the present application, the drawings needed to be used in the embodiments or the prior art descriptions will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present application, and it is obvious for those skilled in the art to obtain other drawings based on these drawings without inventive exercise.
FIG. 1 is a diagram showing the result of a paper diffusion bacteriostasis test;
FIG. 2A is the antibacterial survival rate of the blank control group mice after infection with Listeria monocytogenes;
FIG. 2B is the antibacterial survival rate of positive control mice infected with Listeria monocytogenes;
FIG. 2C is the antibacterial survival rate of negative control mice infected with Listeria monocytogenes;
FIG. 2D shows the survival rate of the rare ginsenoside group-infected mice with Listeria monocytogenes;
FIG. 2E is the antibacterial survival rate of American Ginseng polysaccharide group mice infected with Listeria monocytogenes;
FIG. 2F is the antibacterial survival rate of composition 1 mice after infection with Listeria monocytogenes;
FIG. 2G is the antibacterial survival rate of composition 2 mice after infection with Listeria monocytogenes;
FIG. 2H is the antibacterial survival rate of composition 3 mice after infection with Listeria monocytogenes;
FIG. 2I is the survival rate of the composition 4 mice after infection with Listeria monocytogenes;
FIG. 2J is the antibacterial survival rate of composition 5 mice after infection with Listeria monocytogenes
FIG. 3A is the liver coefficients of normal and Listeria monocytogenes infected mice;
FIG. 3B is the spleen coefficients of normal and Listeria monocytogenes infected mice;
FIG. 4 is a photograph of a liver of a mouse infected with a bacterium and a cut section;
FIG. 5 shows the number of bacterial colonies in the liver tissue of infected mice in the treatment experiment;
FIG. 6A is the level of cytokine IL-6 in the liver of infected mice;
FIG. 6B is the level of cytokine TNF-. alpha.in the liver of infected mice;
FIG. 7A is the survival rate of mice in the placebo group infected with Listeria monocytogenes after intervention;
FIG. 7B is the survival rate of positive control mice infected with Listeria monocytogenes after intervention;
FIG. 7C is the survival rate of negative control mice infected with Listeria monocytogenes following intervention;
FIG. 7D shows survival rate of rare ginsenoside group-infected mice infected with Listeria monocytogenes after intervention;
FIG. 7E is the survival rate of mice with Panax quinquefolium polysaccharide group infected with Listeria monocytogenes after intervention;
FIG. 7F is the survival rate of mice in composition 1 group after intervention with Listeria monocytogenes infection;
FIG. 7G is the survival rate of mice in composition 2 group after intervention with Listeria monocytogenes infection;
FIG. 7H is the survival rate of mice in composition 3 group after intervention with Listeria monocytogenes infection;
FIG. 8 is the number of bacterial colonies in liver tissue of infected mice in the intervention test;
FIG. 9A is a graph of glutamic-pyruvic transaminase levels in livers of infected mice in an intervention test;
FIG. 9B shows the level of glutamic oxaloacetic transaminase in the liver of Chinese infected mice.
Detailed Description
In order to make the technical problems, technical solutions and advantageous effects to be solved by the present application clearer, the present application is further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the present application and are not intended to limit the present application.
Example 1 in vitro antibacterial testing
(1) Preparing a rare ginsenoside component aqueous solution: preparing 2 parts of rare ginsenoside Rb2, 1 part of rare ginsenoside Rd, 10 parts of rare ginsenoside Rg6, 2 parts of rare ginsenoside F4, 8 parts of rare ginsenoside Rh4, 7 parts of rare ginsenoside Rg3, 20 parts of rare ginsenoside Rk1, 25 parts of rare ginsenoside Rg5 and 1 part of rare ginsenoside Rh2, and preparing a 5mg/mL rare ginsenoside component water solution.
(2) The test method comprises the following steps: escherichia coli, Bacillus cereus, Staphylococcus aureus and Listeria monocytogenes are used as experimental objects, meanwhile, a paper piece which is dropwise added with 10 mu L of 5mg/mL American ginseng stem and leaf saponin aqueous solution, 10ul of 5mg/mL macleaya cordata injection and 10 mu L of 5mg/mL penicillin solution is placed on the surface of a culture medium, and the size of the inhibition zone is observed and recorded after the culture for 4-8 h, as shown in figure 1.
In FIG. 1, A is a Listeria monocytogenes culture plate, B is a Staphylococcus aureus culture plate, C is an Escherichia coli culture plate, and D is a Bacillus cereus culture plate. Wherein the serial number of the paper sheet in each plate represents the saponin group of the stems and leaves of the American ginseng, the serial number of the paper sheet 2 represents the rare saponin group of the ginseng, the serial number of the paper sheet 3 represents the macleaya cordata injection group, and the serial number of the paper sheet 4 represents the penicillin control group.
(3) The experimental conclusion is that: as can be seen from FIG. 1, in A, B, C, D four culture plates, the inhibition zones of the saponin groups of stems and leaves of Panax Quinquefolium are all greater than 7.5mm, which indicates that the saponin groups of rare Panax Quinquefolium have antibacterial activity, and the inhibition zones of the saponin groups of rare Panax Quinquefolium are all greater than 10mm, which indicates that the saponin groups of rare Panax Quinquefolium have antibacterial activity, and the antibacterial activity is greater than that of the saponin groups of stems and leaves of Panax Quinquefolium. The bacteriostatic concentration range of the rare ginsenoside component determined by an MIC method MBC method is 0.20-0.80 mg/mL. Moreover, the A, B, C, D four culture plates show that the rare ginsenoside component has strong bacteriostatic activity on escherichia coli and listeria monocytogenes, which shows that the rare ginsenoside component has an inhibiting effect on the growth of drug-resistant bacteria.
Example 2 in vivo antibacterial testing
(1) Preparing a composition aqueous solution of rare ginsenoside and American ginseng polysaccharide: the aqueous solution of the rare ginsenoside group and the American ginseng polysaccharide prepared in example 1 are prepared into aqueous solutions of rare ginsenoside and American ginseng polysaccharide compositions according to the proportion of 1:1, 1:3, 3:1, 1:4 and 4:1, which are respectively marked as composition 1, composition 2, composition 3, composition 4 and composition 5.
(2) The test method comprises the following steps: preparing 10 groups of female mice susceptible to bacterial infection, using group 1 as blank control group, using the rest 9 groups as experimental groups, and injecting 0.1mL 10 mL into abdominal cavity of mice in the experimental groups without any treatment 7 CFU/mL Listeria monocytogenes suspension.
(3) And (3) safety analysis: after the infection, female mice of 8 experimental groups are respectively filled with 10mg/kg of composition 1, 10mg/kg of composition 2, 10mg/kg of composition 3, 10mg/kg of composition 4, 10mg/kg of composition 5, 10mg/kg of rare ginsenoside group, 10mg/kg of American ginseng polysaccharide and 6 million units of penicillin, wherein 6 million units of penicillin is used as a positive control group, female mice of the 10 experimental group are not treated after the infection, and the female mice are used as a negative control group, the survival condition of the mice is observed and recorded within one week, and the survival condition of the mice is shown in fig. 2A-2J.
As can be seen from fig. 2A and 2B, the survival rate of the mice in the blank control group and the positive control group was 100%, and no death phenomenon occurred; as can be seen from fig. 2C, the mice in the negative control group had zero survival rate within 7 days of contamination, i.e., all died; as can be seen from fig. 2D-2J, mice in composition 1, composition 2, composition 3, composition 4, composition 5 and the rare ginsenoside group all had a certain survival rate. As can be seen from the comparison between fig. 2D-fig. 2E and fig. 2F-fig. 2H, the survival rate of the composition 1, the survival rate of the composition 2, and the survival rate of the composition 3 are 73.3%, wherein the survival rate of the mouse in the composition 1 is the highest, the survival rate of the rare ginsenoside group is only 55%, and the survival rate of the American ginseng polysaccharide group is 35%, so that the survival rates of the composition 1, the composition 2, and the composition 3 are all higher than those of the rare ginsenoside group and the American ginseng polysaccharide group, which fully shows that the American ginseng polysaccharide and the rare ginsenoside have a synergistic effect, and the American ginseng polysaccharide has a significant irritation reducing effect and a mortality rate of the organism while the rare ginsenoside has an antibacterial effect on the organism. Thus, the ginseng rare saponin can be applied to a preparation for inhibiting the growth of drug-resistant bacteria, and the American ginseng polysaccharide can be used as an auxiliary agent for reducing the irritation of the ginseng rare saponin.
As shown in the comparison between the fig. 2D-2F and fig. 2I-2J, the survival rates of mice are different due to different ratios of the rare ginsenoside to the American ginseng polysaccharide, and only under the reasonable ratio of the invention, the survival rate of the mice can be maintained at a higher level. Due to the difference caused by the proportion of the rare ginsenoside and the American ginseng polysaccharide, the stability of the drug effect is not high, the risk of adverse reaction of patients in clinical use is increased, and the incidence rate of the adverse reaction is increased year by year. Therefore, the rare ginsenoside and American ginseng polysaccharide composition is applied to the preparation of the drug resistant bacterial infection resisting drug, and the rare ginsenoside and American ginseng polysaccharide are properly matched, so that the rare ginsenoside and American ginseng polysaccharide composition has an antibacterial effect on an organism, can reduce the irritation of the organism and reduce the risk of adverse reaction of a patient, and further improves the medication safety. In addition, the composition of the rare ginsenoside and American ginseng polysaccharide can be applied to the preparation of health care products for preventing drug-resistant bacterial infection.
Example 3 in vivo irritation test
(1) The test method comprises the following steps: preparing 6 groups of female mice susceptible to bacterial infection, using group 1 as blank control group, using the other 5 groups as experimental group, and injecting 0.1mL 10 mL into abdominal cavity of mice in the experimental group without any treatment 7 CFU/mL Listeria monocytogenes suspension.
(2) Stimulation analysis one: after the infection, the female mice of 4 experimental groups were respectively filled with 10mg/kg of the composition 1 prepared in example 2, 10mg/kg of rare ginsenoside group, 10mg/kg of American ginseng polysaccharide and 6 ten thousand units of penicillin, wherein 6 thousand units of penicillin was used as a positive control group, the female mice of the 5 experimental group were not treated after the infection, and were used as a negative group, when the mice were immediately dissected after the end point phenomenon occurred due to infection, the weight of the liver and spleen of the infected mice was measured and recorded, and the test results are shown in fig. 3A-3B. In fig. 3A, the ordinate is the liver coefficient; in fig. 3B, the ordinate is the spleen coefficient.
In FIGS. 3A-3B, Cont represents blank control group, Neg represents negative control group, Pos represents positive control group, HTS represents rare saponin group of Ginseng radix, AGP represents polysaccharide group of radix Panacis Quinquefolii, and HTS + AGP represents composition 1 group. (the same below)
A significant statistical difference compared to the negative control group, P <0.05 indicated by "+"; compared with the blank control group, the group had significant statistical difference, i.e., P <0.05 was indicated by "##", and the group had statistical difference, i.e., P <0.1 was indicated by "#". (the same below)
As can be seen from fig. 3A and 3B, the mouse liver/spleen coefficients of the negative control group (Neg) are most different from the blank control group (Cont), the mouse liver/spleen coefficients of the positive control group (Pos) and the composition 1 group (HTS + AGP) are most similar to the blank control group (Cont), and the mouse liver/spleen coefficients of the ginseng rare saponin group (HTS) and the american ginseng polysaccharide group (AGP) are also more different from the HTS of the blank control group (Cont) than the HTS of the composition 1 group (HTS + AGP) and the blank control group (Cont), which fully indicates that the irritation of the body is least in the composition 1 group (HTS + AGP) compared to the ginseng saponin group (HTS) and the american ginseng polysaccharide group (AGP).
Slicing liver tissue of the 6 groups of infected mice, as shown in A2-F2 in FIG. 4, wherein A-F are respectively mouse liver tissue photographs of a blank control group, a negative control group, a positive control group, a ginseng rare saponin group, an American ginseng polysaccharide group and a composition 1 group; 1 represents a photograph of liver, and 2 represents a liver slice. Arrows in FIGS. A1-F1 indicate pathological changes such as white spots, calcification, etc.; arrows in FIGS. A2-F2 indicate pathological changes such as inflammatory cell infiltration and necrosis.
As can be seen from A1-F1 in FIG. 4, the surface of the liver tissue of mice in the negative control group, the rare ginsenoside group and the American ginseng polysaccharide group has changes such as white spots, calcification and the like; the surfaces of the livers of mice in the blank control group, the positive control group and the composition 1 group have no obvious pathological changes and liver injuries.
As can be seen from A2-F2 in FIG. 4, significant inflammatory cell infiltration and necrosis were seen in the liver sections of mice in the negative control group, rare ginsenoside group of ginseng, and polysaccharide group of Panax quinquefolium; however, the liver tissue sections of the mice of the positive control group and the composition 1 have no obvious pathological changes such as inflammatory cell infiltration and necrosis, and have no obvious difference with the blank control group.
Thus, it can be shown that the irritation of the composition 1 group to the body is minimal compared with the rare ginsenoside group and the American ginseng polysaccharide group. It is well demonstrated that the rare saponin fraction of ginseng used in the present invention can improve liver and kidney damage caused by bacterial infection and can treat listeria monocytogenes infection in mice.
(3) And (4) performing irritation analysis: the number of bacterial colonies in the livers of the infected mice in the above 5 experimental groups was measured, and the measurement results are shown in fig. 5, in which the number of bacterial colonies in the livers of the negative control group (Neg) infected mice was 56, 54.4, and 41 times as large as those in the composition 1 group (HTS + AGP), the ginseng rare saponin group (HTS), and the american ginseng polysaccharide group (AGP), indicating that the bacteriostatic effect of the composition 1 group (HTS + AGP) was the strongest.
The ELISA kit was used to detect the IL-6 and TNF- α levels in the livers of the infected mice, and the results are shown in FIGS. 6A-6B, and in FIG. 6A, the differences between the IL-6 and TNF- α levels in the livers of the mice in the negative control group (Neg) and the blank control group (Cont) were the greatest, and the differences between the IL-6 and TNF- α levels in the livers of the mice in the positive control group (Pos) and the composition 1 group (HTS + AGP) and the blank control group (Cont) were the smallest, compared to the rare ginsenoside group and American ginseng polysaccharide group, thereby indicating that the irritation to the body was the smallest in the composition 1 group. It is well demonstrated that the rare saponin fraction of ginseng used in the present invention can improve liver and kidney damage caused by bacterial infection and can treat listeria monocytogenes infection in mice.
Example 4 in vivo bacterial intervention test
(1) And (3) intervention safety testing: preparing 8 groups of female mice susceptible to bacterial infection, using group 1 as blank control group, using the other 7 groups as experimental groups, and filling 6 groups of female mice with 10mg/kg of composition 1, 10mg/kg of composition 2, 10mg/kg of composition 3, 10mg/kg of rare ginsenoside aqueous solution, 10mg/kg of American ginseng polysaccharide and 6 ten thousand units of penicillin in example 2, wherein 6 ten thousand units of penicillin is containedAs a positive control group, female mice in the 7 th experimental group were subjected to oral gavage pretreatment, and were used as a negative control group, and then 0.1mL 10 was injected into the abdominal cavity of the mice in the 5 th experimental group on the fifteenth day 7 The survival condition of the mice is observed and recorded within one week by CFU/mL Listeria monocytogenes suspension, and the recorded result is shown in figures 7A-7H.
As can be seen from fig. 7A to 7H, after a female Kunming mouse susceptible to bacterial infection is infected with listeria monocytogenes having strong pathogenicity, the mortality rate of the mouse subjected to the intervention of the obtained rare-ginseng saponin and American ginseng polysaccharide composition for 14 days is obviously lower than that of a negative control group without intervention measures, and is also obviously lower than that of a rare-ginseng saponin group and an American ginseng polysaccharide group. Fully indicates that the composition of the rare ginsenoside and the American ginseng polysaccharide can also be used for preparing health care products for preventing drug-resistant bacterial infection.
(2) And (3) intervening bacteriostatic test: the bacterial colony numbers in the livers of the mice infected with bacteria of the negative control group, the positive control group, the composition 1 group, the ginseng rare saponin group and the American ginseng polysaccharide group are measured, the bacterial colony numbers in the livers are shown in figure 8, the bacterial colony numbers in the livers of the mice infected with bacteria of the negative control group (Neg) are 67 times, 61.6 times and 58 times of those of the ginseng rare saponin, American ginseng polysaccharide group, ginseng rare saponin group (HTS) and the positive control group (Pos), and the antibacterial effect of the composition 1 group (HTS + AGP) is the strongest.
(3) And (3) irritation test: median Lethal Dose (LD) via oral administration of rare saponins of ginseng in mice 50 ) Greater than or equal to 5g/Kg, can be considered as basically non-toxic; the contents of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase of the infected mice of the blank control group, the negative control group, the positive control group, the composition 1 group, the ginseng rare saponin group and the American ginseng polysaccharide group are tested, and the measurement results are shown in fig. 9A and 9B.
In fig. 9A and 9B, after the intervention of the rare ginsenoside and american ginseng polysaccharide composition was performed on the mice, the liver functions were tested, and the test results show that the contents of glutamic-pyruvic transaminase and glutamic-oxalacetic transaminase of the mice were not much different from those of mice in the blank control group which were not dried and were not infected, which proves that the rare ginsenoside and american ginseng polysaccharide composition did not cause hepatotoxic damage to the prognosis of the mice. Therefore, the composition of the rare ginsenoside and the American ginseng polysaccharide can be applied to the preparation of health care products for preventing drug-resistant bacterial infection.
In conclusion, the invention provides the composition of rare ginsenoside and American ginseng polysaccharide, through the synergistic effect of the rare ginsenoside and American ginseng polysaccharide conjugate, the rare ginsenoside is capable of killing and inhibiting in-vivo bacteria, and the existence of the American ginseng polysaccharide reduces the irritation of the rare ginsenoside and improves the immunity synergistically, reduces the death rate of drug-resistant bacterial infection of organisms, and relieves the use limit of the rare ginsenoside and the American ginseng polysaccharide which are used independently. On the basis, the effect difference of the rare ginsenoside and the American ginseng polysaccharide with different proportions is further researched to obtain the composition of the rare ginsenoside and the American ginseng polysaccharide, and the composition of the rare ginsenoside and the American ginseng polysaccharide is applied to preparing the drug for resisting drug-resistant bacterial infection. In addition, based on the principle, the composition of the rare ginsenoside and American ginseng polysaccharide can also be used for preparing health care products for preventing drug-resistant bacterial infection.
The above description is only exemplary of the present application and should not be taken as limiting the present application, as any modification, equivalent replacement, or improvement made within the spirit and principle of the present application should be included in the protection scope of the present application.

Claims (7)

1. The composition of rare ginsenoside and American ginseng polysaccharide is characterized by comprising the rare ginsenoside and the American ginseng polysaccharide, wherein the weight part ratio of the rare ginsenoside to the American ginseng polysaccharide is 1:3-3: 1.
2. the composition of rare ginsenoside and American ginseng polysaccharide as in claim 1, wherein the rare ginsenoside comprises rare ginsenoside Rb2, rare ginsenoside Rd, rare ginsenoside Rg6, rare ginsenoside F4, rare ginsenoside Rh4, rare ginsenoside Rg3, rare ginsenoside Rk1, rare ginsenoside Rg5 and rare ginsenoside Rh 2.
3. The composition of rare ginsenoside and American ginseng polysaccharide as claimed in claim 2, wherein the rare ginsenoside comprises the following components in parts by weight: comprises 2 parts of rare ginsenoside Rb2, 1 part of rare ginsenoside Rd, 10 parts of rare ginsenoside Rg6, 2 parts of rare ginsenoside F4, 8 parts of rare ginsenoside Rh4, 7 parts of rare ginsenoside Rg3, 20 parts of rare ginsenoside Rk1, 25 parts of rare ginsenoside Rg5 and 1 part of rare ginsenoside Rh 2.
4. The application of the composition of rare ginsenoside and American ginseng polysaccharide in preparing a medicament for resisting drug-resistant bacterial infection is characterized in that the composition of rare ginsenoside and American ginseng polysaccharide in any one of claims 1 to 3 is applied to preparing a medicament for resisting drug-resistant bacterial infection.
5. An application of a composition of rare ginsenoside and American ginseng polysaccharide, which is characterized in that the composition of rare ginsenoside and American ginseng polysaccharide in any one of claims 1 to 3 is applied to the preparation of health care products for preventing drug-resistant bacterial infection.
6. The use of the composition of rare saponins of panax ginseng and american ginseng polysaccharides as claimed in claim 4 or 5, wherein the use of rare saponins of panax ginseng in the preparation of a drug-resistant bacterial growth inhibitor.
7. The use of the rare saponins of panax ginseng and american ginseng polysaccharides composition of claim 4 or 5, wherein the american ginseng polysaccharides are used as an adjuvant to reduce the irritation of rare saponins of panax ginseng and to synergistically enhance immunity.
CN202210298951.6A 2022-03-25 2022-03-25 Composition of rare ginsenoside and American ginseng polysaccharide and application thereof Pending CN114848695A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210298951.6A CN114848695A (en) 2022-03-25 2022-03-25 Composition of rare ginsenoside and American ginseng polysaccharide and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210298951.6A CN114848695A (en) 2022-03-25 2022-03-25 Composition of rare ginsenoside and American ginseng polysaccharide and application thereof

Publications (1)

Publication Number Publication Date
CN114848695A true CN114848695A (en) 2022-08-05

Family

ID=82629804

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210298951.6A Pending CN114848695A (en) 2022-03-25 2022-03-25 Composition of rare ginsenoside and American ginseng polysaccharide and application thereof

Country Status (1)

Country Link
CN (1) CN114848695A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432454B1 (en) * 1997-12-12 2002-08-13 C. V. Technologies, Inc. Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
US20020136785A1 (en) * 2000-11-07 2002-09-26 Chun-Su Yuan Ginseng berry extracts and pharmaceutical compositions from ginseng berry for the treatment of type 2 diabetes and obesity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432454B1 (en) * 1997-12-12 2002-08-13 C. V. Technologies, Inc. Processes of making north american ginseng fractions, products containing them, and use as immunomodulators
US20020136785A1 (en) * 2000-11-07 2002-09-26 Chun-Su Yuan Ginseng berry extracts and pharmaceutical compositions from ginseng berry for the treatment of type 2 diabetes and obesity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
王德富著: "中国东北三宝之首 百草之王 轻身延年 人参怎么吃", 吉林音像出版社 *
都晓伟 等: "西洋参加工品西洋红参中皂苷及糖类成分的分析", 中医药学报 *

Similar Documents

Publication Publication Date Title
EP3634444B1 (en) Compositions for use in the treatment of helicobacter pylori
EP2486922A1 (en) Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof
JP2017529400A (en) Mangosteen extract or composition for preventing or ameliorating periodontal disease comprising alpha and gamma mangosteen as active ingredients
JP2012121914A (en) Alleviator for radiation disorder
CN102940595A (en) Mouthwash with functions of antibiosis, antiphlogosis and deodorization, and preparation method and use thereof
CN108056928B (en) A kind of buccal cavity gel of the rare saponin(e containing Radix Notoginseng and preparation method thereof
KR102217525B1 (en) Probiotics for prevention or treatment of periodontitis and use thereof
CN114848695A (en) Composition of rare ginsenoside and American ginseng polysaccharide and application thereof
KR20140124960A (en) A composition containing cryptotanshinone as a active ingredient for the treatment of dental caries and peridontal disease
US11173101B1 (en) Silver ion bacteriostatic hand sanitizer and preparation method and application thereof
KR102465484B1 (en) Pharmaceutical composition for the prevention or treatment of obesity or metabolic syndrome induced from obesity containing heat-killed enteroccocus faecalis as an active ingredient
KR20190006285A (en) Antibacterial composition comprising an extract of schisandra chinesis
DE102008059070A1 (en) Composition, useful for therapeutic or prophylactic treatment of diarrhea and to maintain the natural intestinal flora comprises combination of microorganisms that positively influence the intestinal flora and a prebiotic
CN106344453A (en) Novel acne cream and preparation method thereof
KR20160103547A (en) Antioxidant composition containing purified bee venom
KR101280868B1 (en) Pharmaceutical and food composition for preventing or treating cavity and periodontal disease comprising extract of Yacon as effective component
Tiwari et al. Comparison of antibacterial efficacy of aqueous suspension, alcoholic extract and their combination of Stevia rebaudiana against two cariogenic organisms-an in-vitro study
KR20150136656A (en) Compositions for preventing, improving or treating periodontal diseases
KR101555214B1 (en) A composition containing sophoraflavanone g as a active ingredient for the treatment of dental caries and peridontal disease
CN103405481B (en) Medicinal composition containing staphylococcus albus and preparation method thereof
KR20140147967A (en) Composition comprising fermented Oenanthe Javanica organic acid extract for anti-inflammation
CN102334712B (en) Preparation method of solution for improving enteric microorganisms
RU2248212C2 (en) Preparation for treatment of bacterial vaginitis, method for its preparing and method for treatment of bacterial vaginitis
CN110179810B (en) A pharmaceutical composition with anti-tumor effect
US20220184152A1 (en) Composition for modulating immunity and the use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination